ACRS (Aclaris Therapeutics) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Aclaris Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aclaris Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Aclaris Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Aclaris Therapeutics's Cash-to-Debt or its related term are showing as below:

ACRS' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.81 Med: 841.64 Max: No Debt
Current: No Debt

During the past 12 years, Aclaris Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 4.81. And the median was 841.64.

ACRS's Cash-to-Debt is ranked better than
99.55% of 223 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.22 vs ACRS: No Debt

Aclaris Therapeutics Cash-to-Debt Historical Data

The historical data trend for Aclaris Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Aclaris Therapeutics Cash-to-Debt Chart

Aclaris Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

4.81

276.21

318.09

No Debt

Aclaris Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Aclaris Therapeutics's Cash-to-Debt

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aclaris Therapeutics's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Aclaris Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Aclaris Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Aclaris Therapeutics had no debt ⁽¹⁾.

Aclaris Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Aclaris Therapeutics had no debt ⁽¹⁾.

Aclaris Therapeutics (NAS:ACRS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Aclaris Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclaris Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (NAS:ACRS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

0H8T:UK 8AT:Germany

Address

701 Lee Road, Suite 103, Wayne, PA, USA, 19087

Website

https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Executives

Anand Mehra	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Joseph Monahan	officer: Chief Scientific Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Kevin Balthaser	officer: Chief Financial Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
James Loerop	officer: Chief Business Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Douglas J. Manion	officer: Pres and COO	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Neal Walker	director, officer: President and CEO	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Andrew N Schiff	director	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Gail Cawkwell	officer: Chief Medical Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Frank Ruffo	officer: Chief Financial Officer	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
David N. Gordon	officer: Chief Medical Officer	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Kamil Ali-jackson	officer: Chief Legal Officer	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
James B. Tananbaum	10 percent owner	3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
Foresite Capital Management Iii, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iii, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund Iv, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111